Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.75 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.75 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.61 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | MTOR | P42345 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700710 | 0.86 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL679320 | 0.86 | SLC6A4 (1.00) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL5570738 | 0.84 | SLC6A4 (0.81) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL8971141 | 0.84 | SLC6A4 (0.81) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL5409319 | 0.83 | SLC6A4 (0.75) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL7943264 | 0.82 | SLC6A4 (0.79) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL11925287 | 0.82 | SLC6A4 (0.79) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL10076387 | 0.82 | SLC6A4 (0.79) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL3415108 | 0.82 | SLC6A4 (0.78) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 | |
| SCHEMBL21034469 | 0.81 | SLC6A4 (0.77) | SLC6A4HRH3SLC6A9SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | CONJUCHEM, INC. (CA) | 2004-08-12 | — | — | US | disclosed |
| US-6706892-B1 | ADMINSTERING MALEIMIDE DERIVATIVE TO COVALENTLY BOND PROTEIN; WOUND HEALING, ANTIBIOTIC, ANTIINFLAMMATORY, ANTICARCINOGENIC, HYPOTENSIVE, AND ANALGESIC AGENTS | CONJUCHEM, INC. (CA) | 2004-03-16 | — | — | US | disclosed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | disclosed |
| EP-0929514-A1 | PROCESS FOR THE PREPARATION OF FLUOXETINE | EGIS GYOGYSZERGYAR RT. (HU) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998011054-A1 | PROCESS FOR THE PREPARATION OF FLUOXETINE | EGIS Gyógyszergyár Rt. (HU) | 1998-03-19 | — | — | WO | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | OGFR, HDGF, SERPINA6 | SLC6A4 729/4885HRH3 175/4885SLC6A9 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.